Year-end Sale % OFF 
Abstract
We performed a retrospective analysis of 9 patients with acute myeloid leukemia (AML) treated with gemtuzumab ozogamicin (GO) plus cytarabine as a salvage regimen (GO reinduction) for patients who did not achieve complete remission (CR) after the first cycle of induction chemotherapy or at first relapse. Cases of AML secondary to myelodysplastic syndrome or myeloproliferative disorder were included. CR was achieved in 6 of 9 patients, and 2 of 6 responders became long-term survivors. No non-responders survived longer than 6 months. Toxicity was mild, and the median duration of myelosuppression was less than 30 days. Stomatitis, nausea and sepsis occurred as non-hematological adverse events. Although our sample size was too small to permit definitive conclusions, GO reinduction should be considered for patients who relapse or do not achieve CR after the first cycle of induction chemotherapy. Some AML subtypes may respond more robustly than others, and further investigation is warranted.
Highlights
The mainstay of induction chemotherapy for acute myeloid leukemia (AML), cytarabine (AraC) and anthracycline, achieves remission in 70% - 80% of untreated patients younger than 60 years of age [1] [2]
In elderly patients (≥60 years old), the remission rate is less than 50% and the long-term leukemia-free survival rate is less than 10% [4]
Two patients (Nos. 3 and 6) had AML secondary to myelodysplastic syndrome (MDS), and 1 (No 9) had AML transformed from essential thrombocythemia
Summary
The mainstay of induction chemotherapy for acute myeloid leukemia (AML), cytarabine (AraC) and anthracycline, achieves remission in 70% - 80% of untreated patients younger than 60 years of age [1] [2]. In elderly patients (≥60 years old), the remission rate is less than 50% and the long-term leukemia-free survival rate is less than 10% [4]. Patients who do not achieve complete remission (CR) after the first cycle of induction chemotherapy are retreated with their original regimen or with AraC and another anthracycline. Long-term outcomes are similar for patients who require 1 versus 2 cycles of induction therapy to achieve CR [5], whether or not the patient achieves CR is critical. Therapeutic strategies for patients with relapsed AML are limited, but a small percentage of these patients do achieve remission by salvage or reinduction chemotherapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
